Processing

Please wait...

Settings

Settings

1. WO1991000360 - BISPECIFIC REAGENTS FOR AIDS THERAPY

Publication Number WO/1991/000360
Publication Date 10.01.1991
International Application No. PCT/US1990/003751
International Filing Date 29.06.1990
Chapter 2 Demand Filed 21.01.1991
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 14/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
C07K 14/73 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
73CD4
C07K 16/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/6839
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6839the antibody targeting material from viruses
A61K 47/6849
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6849the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
A61K 47/6879
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6875the antibody being a hybrid immunoglobulin
6879the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Applicants
  • MEDAREX, INC. [US/US]; 20 Nassau Street Princeton, NJ 08542, US
Inventors
  • FANGER, Michael, W.; US
  • GUYRE, Paul, M.; US
  • DINCES, Nathan, B.; US
Agents
  • DeCONTI, Giulio, A., Jr. ; Lahive & Cockfield 60 State Street Boston, MA 02109-1803, US
Priority Data
373,90529.06.1989US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BISPECIFIC REAGENTS FOR AIDS THERAPY
(FR) REACTIFS BISPECIFIQUES POUR LE TRAITEMENT DU SIDA
Abstract
(EN)
Bispecific molecules which react both with the high-affinity Fc$g(g) receptor of human effector cells and with a virus or virus component are disclosed. Binding of the molecules to the Fc receptors found on effector cells is not blocked by human immunoglobulin G. The molecules are useful for targeting human effector cells (e.g. macrophages) against a viral target (e.g. HIV or HIV-infected cell). For this purpose, bispecific molecules can be constructed containing the binding region derived from an anti-Fc$g(g) receptor antibody and the CD4 molecule or CD4 binding domain of the envelope glycoprotein gp120 of HIV. Alternatively, bispecific antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a HIV-specific antibody such as anti-gp120 antibody. Targeted effector cells can be used to kill virus by cell mediated antibody dependent cytolysis.
(FR)
Des molécules bispécifiques qui réagissent avec le récepteur à grande affinité Fc$g(g) de cellules effectrices humaines et avec un virus ou une composante de virus sont décrites. La liaison des molécules aux récepteurs Fc trouvés sur les cellules effectrices n'est pas bloquée par l'immunoglobuline humaine G. Les molécules sont utiles pour cibler les cellules effectrices humaines (par exemple macrophage) contre une cible virale HIV ou une cellule infectée par le HIV. Pour cela, on peut construire des molécules bispécifiques qui contiennent la région liante dérivée d'un anticorps récepteur anti-Fc$g(g) et de la molécule CD4 ou le domaine de liaison CDA de l'enveloppe glycoprotéine gp120 du HIV. On peut également construire des anticorps bispécifiques ou des hétéro-anticorps qui contiennent la région de liaison dérivée d'un anticorps récepteur anti-Fc et la région liante d'un anticorps spécifique du HIV, comme par exemple un anticorps anti-gp120. Les cellules effectrices ciblées peuvent être utilisées pour tuer le virus par cytolyse liée à l'anticorps grâce à la médiation cellulaire.
Also published as
Latest bibliographic data on file with the International Bureau